Palperidone prolonged release “depot” injection (Xeplion®)
Palperidone is the main active metabolite of risperidone and has been available in tablet form (Invega).
It is licensed for the maintenance treatment of schizophrenia. As expected, paliperidone prolonged release injection has similar efficacy to risperidone long-acting injection (Risperdal Consta®), but it has some advantages:
- It does not require storage in a fridge
- The dose can be given monthly (12 injections per year), whereas risperidone LA injection is administered every fortnight
- No oral supplementation is required during initial dosing period
However, the initial dose regimen consists of an initial loading dose (150mg deltoid), followed by a further dose (100mg deltoid) one week later. Thereafter, monthly doses of 75mg are recommended (deltoid or gluteal route). The monthly maintenance doses are recommended within the range of 50mg to 150mg.
Further details are available from Janssen – email@example.com
Photo taken from here. No change needed.